GSK Canada
Canadian operations of a global biopharmaceutical company. Core activities in Canada include vaccine manufacturing and domestic supply planning, vaccine and biologic R&D, clinical trial design and execution, genomics and AI/ML-enabled discovery, regulatory and pharmacovigilance programs, quality control testing, patient support programs and partnerships with academic and community stakeholders.
Industries
Nr. of Employees
small (1-50)
GSK Canada
GSK, Attn: GSK Customer Service, 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1, Canada
Products
Vaccines portfolio
Marketed vaccines spanning recombinant, adjuvanted, conjugate, inactivated and live‑attenuated platforms for prevention across the lifespan.
Specialty medicines
Specialist-prescribed medicines for areas including HIV, oncology and immune-mediated diseases.
General medicines
Primary-care medicines including inhaled respiratory therapies and anti-infectives.
Vaccines portfolio
Marketed vaccines spanning recombinant, adjuvanted, conjugate, inactivated and live‑attenuated platforms for prevention across the lifespan.
Specialty medicines
Specialist-prescribed medicines for areas including HIV, oncology and immune-mediated diseases.
General medicines
Primary-care medicines including inhaled respiratory therapies and anti-infectives.
Services
Design, sponsorship and operational support for clinical studies and investigator-sponsored trials across Canada.
Large-scale on-site production of vaccines with integrated downstream operations and domestic distribution planning.
Collaborative programs and sponsored projects with academic institutions and research consortia to accelerate discovery and commercialization.
Programs providing reimbursement navigation, drug administration support, pharmacy coordination, financial assistance and access solutions for eligible patients.
Structured grant-making and partnerships supporting patient groups, public health initiatives and education programs.
Design, sponsorship and operational support for clinical studies and investigator-sponsored trials across Canada.
Large-scale on-site production of vaccines with integrated downstream operations and domestic distribution planning.
Collaborative programs and sponsored projects with academic institutions and research consortia to accelerate discovery and commercialization.
Programs providing reimbursement navigation, drug administration support, pharmacy coordination, financial assistance and access solutions for eligible patients.
Structured grant-making and partnerships supporting patient groups, public health initiatives and education programs.
Expertise Areas
- Clinical trial management
- Vaccine manufacturing and downstream processing
- Vaccine and biologic formulation development
- Genomics and biomarker research
Key Technologies
- Artificial intelligence / machine learning
- Genomic and genetic analysis
- Recombinant vaccine production methods
- Adjuvanted and conjugate vaccine platforms
News & Updates
Press release announcing provincial reimbursement for a specialty medicine for myelofibrosis.
Press release summarizing a survey on RSV awareness and risk understanding among older adults.
Press release reporting study findings on an association between heart disease and shingles risk.
Press release announcing a philanthropic investment to support a lung wellness clinic in Nova Scotia.
Announcement of a letter of intent between the company and pCPA regarding reimbursement negotiations for a specialty medicine.
Announcement that an RSV vaccine product has been included in publicly funded prevention programs for older adults.
Press release announcing provincial reimbursement for a specialty medicine for myelofibrosis.
Press release summarizing a survey on RSV awareness and risk understanding among older adults.
Press release reporting study findings on an association between heart disease and shingles risk.
Press release announcing a philanthropic investment to support a lung wellness clinic in Nova Scotia.
Announcement of a letter of intent between the company and pCPA regarding reimbursement negotiations for a specialty medicine.
Announcement that an RSV vaccine product has been included in publicly funded prevention programs for older adults.